Diagnostic Performance of Dynamic Contrast-Enhanced 3T MR Imaging for Characterization of Orbital Lesions: Validation in a Large Prospective Study.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 06 10 2023
accepted: 05 12 2023
medline: 8 3 2024
pubmed: 8 3 2024
entrez: 7 3 2024
Statut: epublish

Résumé

Orbital lesions are rare but serious. Their characterization remains challenging. Diagnosis is based on biopsy or surgery, which implies functional risks. It is necessary to develop noninvasive diagnostic tools. The goal of this study was to evaluate the diagnostic performance of dynamic contrast-enhanced MR imaging at 3T when distinguishing malignant from benign orbital tumors on a large prospective cohort. This institutional review board-approved prospective single-center study enrolled participants presenting with an orbital lesion undergoing a 3T MR imaging before surgery from December 2015 to May 2021. Morphologic, diffusion-weighted, and dynamic contrast-enhanced MR images were assessed by 2 readers blinded to all data. Univariable and multivariable analyses were performed. To assess diagnostic performance, we used the following metrics: area under the curve, sensitivity, and specificity. Histologic analysis, obtained through biopsy or surgery, served as the criterion standard for determining the benign or malignant status of the tumor. One hundred thirty-one subjects (66/131 [50%] women and 65/131 [50%] men; mean age, 52 [SD, 17.1] years; range, 19-88 years) were enrolled. Ninety of 131 (69%) had a benign lesion, and 41/131 (31%) had a malignant lesion. Univariable analysis showed a higher median of transfer constant from blood plasma to the interstitial environment ( Dynamic contrast-enhanced MR imaging at 3T appears valuable when characterizing orbital lesions and provides complementary information to morphologic imaging and DWI.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Orbital lesions are rare but serious. Their characterization remains challenging. Diagnosis is based on biopsy or surgery, which implies functional risks. It is necessary to develop noninvasive diagnostic tools. The goal of this study was to evaluate the diagnostic performance of dynamic contrast-enhanced MR imaging at 3T when distinguishing malignant from benign orbital tumors on a large prospective cohort.
MATERIALS AND METHODS METHODS
This institutional review board-approved prospective single-center study enrolled participants presenting with an orbital lesion undergoing a 3T MR imaging before surgery from December 2015 to May 2021. Morphologic, diffusion-weighted, and dynamic contrast-enhanced MR images were assessed by 2 readers blinded to all data. Univariable and multivariable analyses were performed. To assess diagnostic performance, we used the following metrics: area under the curve, sensitivity, and specificity. Histologic analysis, obtained through biopsy or surgery, served as the criterion standard for determining the benign or malignant status of the tumor.
RESULTS RESULTS
One hundred thirty-one subjects (66/131 [50%] women and 65/131 [50%] men; mean age, 52 [SD, 17.1] years; range, 19-88 years) were enrolled. Ninety of 131 (69%) had a benign lesion, and 41/131 (31%) had a malignant lesion. Univariable analysis showed a higher median of transfer constant from blood plasma to the interstitial environment (
CONCLUSIONS CONCLUSIONS
Dynamic contrast-enhanced MR imaging at 3T appears valuable when characterizing orbital lesions and provides complementary information to morphologic imaging and DWI.

Identifiants

pubmed: 38453407
pii: 45/3/342
doi: 10.3174/ajnr.A8131
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

342-350

Informations de copyright

© 2024 by American Journal of Neuroradiology.

Auteurs

Emma O'Shaughnessy (E)

From the Department of Neuroradiology (E.O., J.S., L.D., A.L.), Rothschild Foundation Hospital, Paris, France eoshaughnessy@for.paris.

Chloé Le Cossec (CL)

Department of Clinical Research (C.L.C., A.L.), Rothschild Foundation Hospital, Paris, France.

Natasha Mambour (N)

Department of Ophthalmology (N.M., M.Z.), Rothschild Foundation Hospital, Paris, France.

Adrien Lecoeuvre (A)

Department of Clinical Research (C.L.C., A.L.), Rothschild Foundation Hospital, Paris, France.

Julien Savatovsky (J)

From the Department of Neuroradiology (E.O., J.S., L.D., A.L.), Rothschild Foundation Hospital, Paris, France.

Mathieu Zmuda (M)

Department of Ophthalmology (N.M., M.Z.), Rothschild Foundation Hospital, Paris, France.

Loïc Duron (L)

From the Department of Neuroradiology (E.O., J.S., L.D., A.L.), Rothschild Foundation Hospital, Paris, France.

Augustin Lecler (A)

From the Department of Neuroradiology (E.O., J.S., L.D., A.L.), Rothschild Foundation Hospital, Paris, France.

Classifications MeSH